Jazz Pharmaceuticals (JAZZ) EBT (2010 - 2026)

Jazz Pharmaceuticals' EBT history runs 17 years deep, the most recent figure standing at $299.2 million for Q1 2026.

• In Q1 2026, EBT rose 372.5% year-over-year to $299.2 million; the TTM figure through Mar 2026 stood at -$218.8 million (down 160.43% YoY), while the FY2025 annual figure was -$627.9 million, down 233.49% from the prior year.
• EBT was $299.2 million for Q1 2026 at Jazz Pharmaceuticals, up from $208.5 million in the prior quarter.
• In the past five years, EBT ranged from a high of $299.2 million in Q1 2026 to a low of -$735.6 million in Q2 2025.
• Historically, EBT has averaged $3.9 million across 5 years, with a median of $55.1 million in 2023.
• The sharpest annual moves came in 2023 and 2025: EBT jumped 771.16% in 2023, then plunged 6753.93% in 2025.
• A 5-year view of EBT shows it stood at -$340.0 million in 2022, then jumped by 118.1% to $61.5 million in 2023, then surged by 116.52% to $133.2 million in 2024, then soared by 56.49% to $208.5 million in 2025, then jumped by 43.52% to $299.2 million in 2026.
• The last three EBT figures came in at $299.2 million (Q1 2026), $208.5 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.